Intrinsically Fluorescent Oligomeric Cytotoxic Conjugates Toxic for FGFR1-Overproducing Cancers

Natalia Porębska1, Agata Knapik1, Marta Poźniak1

  • 1Faculty of Biotechnology, Department of Protein Engineering, University of Wroclaw, Joliot-Curie 14a, Wroclaw 50-383, Poland.

Biomacromolecules
|December 2, 2021
PubMed

Insights

Researchers developed novel fluorescent, self-assembling conjugates targeting Fibroblast Growth Factor Receptor 1 (FGFR1) for cancer therapy. These conjugates show high affinity, efficient internalization, and potent cytotoxicity against FGFR1-overexpressing cancer cells.

Area of Science:

  • Bioconjugation chemistry
  • Molecular oncology
  • Drug delivery systems

Background:

  • Fibroblast Growth Factor Receptor 1 (FGFR1) overexpression is common in various cancers, making it a promising target for anticancer therapies.
  • Developing targeted therapies requires molecules with high affinity and efficient cellular uptake for specific cancer cells.

Purpose of the Study:

  • To create intrinsically fluorescent, self-assembling, oligomeric cytotoxic conjugates targeting FGFR1.
  • To evaluate the efficacy of these conjugates as imaging agents and drug carriers for FGFR1-overexpressing cancers.

Main Methods:

  • Genetically fusing Fibroblast Growth Factor 1 (FGF1) to green fluorescent protein polygons (GFPp) to create GFPp_FGF1 oligomers.
  • Engineering a trimeric GFPp_FGF1 variant with FGF1-stabilizing mutations and site-specific incorporation of monomethyl auristatin E (MMAE).
  • Assessing the conjugate's affinity, stability, cellular internalization, and cytotoxicity in FGFR1-expressing cancer cells.

Main Results:

  • The engineered conjugate, 3xGFPp_FGF1E_LPET_MMAE, demonstrated nanomolar affinity and high stability for FGFR1.
  • Intrinsic fluorescence allowed tracking of efficient and selective cellular internalization into FGFR1-expressing cells.
  • The conjugate exhibited potent cytotoxicity against FGFR1-overproducing cancer cells while sparing FGFR1-negative cells.

Conclusions:

  • Engineered intrinsically fluorescent, self-assembling cytotoxic conjugates are effective for targeting FGFR1.
  • These conjugates hold potential for both imaging and targeted therapy of cancers with aberrant FGFR1 expression.